Announcements Trials
Browse Landscape

Phase

Phase 2 59Phase 3 26Phase 1/2 14Phase 1 12Phase NA 3Phase 2/3 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 11Esophageal Squamous Cell Carcinoma 8Esophageal Neoplasms 7Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Nasopharyngeal Carcinoma 6Lung Neoplasms 6Head and Neck Neoplasms 5Gallbladder Neoplasms 5Cholangiocarcinoma 5Pancreatic Neoplasms 4Mesothelioma 4Breast Neoplasms 4Biliary Tract Neoplasms 4Stomach Neoplasms 3Oropharyngeal Neoplasms 3Neoplasm Metastasis 3Carcinoma 3Urinary Bladder Neoplasms 2Osteosarcoma 2Neoplasms 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Squamous Cell 2Bile Duct Neoplasms 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Thymoma 1Thymic epithelial tumor 1Testicular Neoplasms 1

Interventions

Gemcitabine 6Carboplatin 3valrubicin 2Cisplatin 2vinflunine 1toripalimab 1pertuzumab 1disitamab vedotin 1cabazitaxel 1apaziquone 1XRP6258 1Watchful Waiting 1Vinblastine 1Trastuzumab 1Transurethral Resection of Bladder 1Tranexamic Acid 1Saline Solution 1RC48 antibody 1Oncolytic Virotherapy 1Mitomycin 1Methotrexate 1Magnetic Resonance Spectroscopy 1Lapatinib 1Interferons 1Interferon-alpha 1Gabapentin 1Circulating Tumor DNA 1Celecoxib 1BCG Vaccine 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Urinary Bladder Neoplasms × Cisplatin × Clear all
NCT07129993 2026-05-14

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Daiichi Sankyo

Phase 2/3 Recruiting
630 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07106762 2026-05-12

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Bristol-Myers Squibb

Phase 2/3 Recruiting
470 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡